A Look Under the Rug at the Savvy Penetration of Europe’s Cannabis Market by Supreme Heights
September 6th, 2019
App, Exclusive, News, Top News
As the nascent European legal cannabis market emerges, Canadian companies that have cut their teeth in their home markets are taking that experience overseas to capitalize on a much larger market opportunity. The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) is a model of how to build a successful cannabis portfolio at a blistering pace. And the way that they just made their move into Europe was savvy, to say the least.
There are about 37 million people in Canada. There are over 513 million people in the European Union, of which around 480 million citizens have access to medical cannabis in some way, shape or form. Of the 28 members of the E.U. (including the U.K. at this point), only Bulgaria, Hungary, Latvia, Slovakia and Sweden are still steadfast on cannabis being illegal in all forms, including cannabis-based drug derivatives.
Canada is undoubtedly a global leader, cementing its position in history last year as the first industrialized country – and second country ever behind Uruguay – to legalize recreational marijuana for adults. The setting of the framework was invaluable to pioneering cannabis companies and management. When the dust settles in the future, the sheer volume of potential patients (>12x more) suggests that the European markets will be much larger than that of Canada, providing a once-in-a-lifetime opportunity to put that experience to use.
Like everything else cannabis, just how big the market will be is subjective, but it will be huge regardless of guesstimate. For example, in its ‘The European Cannabis Report,’ Prohibition Partners said earlier this year that it sees Europe as the world’s biggest legal cannabis market in the next five years and reaching up to €123 billion (US$136.7 billion) by 2028.
Executional Excellence: This is How You Do It
In about three years, Supreme Cannabis has built and scaled its cannabis business in Canada, while more recently stepping into global markets through deals in Malta and Lesotho.
The Supreme portfolio currently consists of six subsidiaries, covering a swath of the cannabis industry, including IP discovery, cultivation, production (of multiple goods) and sales into eight Canadian provinces. Some of this has been organic growth, while some, such as the recent acquisitions of Truverra and Blissco, has been inorganic. The flagship brand in the family is 7ACRES, which expanded its cultivation capacity in just 12 months from 3,000 square feet to 230,000 square feet for production capacity of 33,580 kilograms.
Nothing speaks more clearly to the ability to scale than Supreme this month providing revenue guidance for the next year in the range of $150 million to $180 million. If it makes good on this guidance, Supreme will have become one of the top cannabis companies in the world based upon annual revenue in less than five years.
The robust growth is owed to management’s ability to make prescient moves to stay in front of regulation changes in addition to operational excellence. This includes not only the recreational cannabis market as it stands today, but also the upcoming new laws in Canada anticipated for October.
The upcoming changes include cannabis extracts becoming available to Canadians. To position for market share, Supreme has partnered with PAX Labs, the top-selling pen-and-pod system in the U.S., for new premium pods for sale with the PAX Era systems in Canada. Supreme has also partnered with Wiz Khalifa’s Khalifa Kush Enterprises Canada to bring the popular U.S. brand to Canadians.
Overseas, Supreme leadership made the prescient decision to strike a supply agreement and to invest $10 million in Medigrow Lesotho, a leading licensed medical cannabis oil producer in the Kingdom of Lesotho. Lesotho is a land-locked country surrounded entirely by South Africa, a country of 57 million that changed its laws in May to allow for legal sales of CBD (cannabidiol) products.
Reaching Supreme Heights
Looking ahead to the burgeoning European cannabis markets, Supreme in June launched Supreme Heights, a London, England-based investment platform focused on CBD opportunities throughout Europe. The astute launch brought the company’s leadership, extensive comprehension of regulations, premium product commercialization, supply chains, marketing, capital markets and corporate support services to promising European upstarts who are seeking capital.
Patrick Morton, co-founder of Cannabis Invest UK, the leading cannabis investor conference in the country, has assumed the role of CEO of Supreme Heights with key members of existing Supreme Cannabis leadership joining the team. Morton has spent years developing an expansive network of local and global cannabis and CBD companies.
Getting Morton involved once again points to the savvy decision making of Supreme. In one fell swoop, Supreme Cannabis has gotten unfettered access to Morton’s network, effectively giving it the opportunity to begin culling European companies for potential investments.
Oozing with Business Acumen
The relationship is bi-lateral for Supreme Cannabis. The obvious is investment arm and ROI that can result in high-margin revenue for the parent company by putting out its capital and lending some developmental and operational advice.
A second aspect was hit on by Morton when he said, “With guidance from Supreme Cannabis, we intend to make targeted investments in wellness brands that provide exposure to value-add categories in the UK and Europe’s CBD market, including vaporizers, edibles and beverages, topicals and ancillary services.”
On the surface, this can be taken just literally because Supreme has experience in all these facets of the business. A read between the lines signals that Supreme indeed intends to make investments in European companies, as well as using the relationships as inroads to more business to further support the top and bottom lines.
This is further understood with some “big picture” vision aggregating moves Supreme has made in the recent past. The acquisition of Truverra came with the company’s European subsidiary, Netherlands-based Truverra (Europe) B.V., which already has small-scale sales of its eponymous hemp-derived CBD products through its established distribution channels in the U.K. and Netherlands.
Don’t forget that Medigrow Lesotho, which already has over 400 employees, is building a facility expected to be an EU-compliant GMP facility for exports of CBD oils. Blissco’s current facility was also built to be EU-compliant GMP and will be capable of producing over 7 million bottles of tinctures in the next few months.
Against this backdrop, it is Navdeep Dhaliwal, CEO of Supreme Cannabis, probably said it most concisely with, “We look forward to driving value for Supreme Cannabis shareholders through this investment platform.”
Given the way Supreme took Canada by storm, it shouldn’t come as any surprise that they will take an equally aggressive approach to tackle the much bigger European markets.
CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com(the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.